title: [Therapy of atopic eczema with calcineurin inhibitors].
authors.affiliation: Hautklinik, Universitätsklinikkum Münster, Deutschland. luger@uni-muenster.de
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Luger
authors.forename: Thomas
authors.initials: T
authors.lastname: Bieber
authors.forename: Michael
authors.initials: M
authors.lastname: Meurer
authors.forename: Ulrich
authors.initials: U
authors.lastname: Mrowietz
authors.forename: Thomas
authors.initials: T
authors.lastname: Schwarz
authors.forename: Jan
authors.initials: J
authors.lastname: Simon
authors.forename: Thomas
authors.initials: T
authors.lastname: Werfel
authors.forename: Torsten
authors.initials: T
authors.lastname: Zuberbier
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000465:Algorithms; D065095:Calcineurin Inhibitors; D002648:Child; D002675:Child, Preschool; D018849:Controlled Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D004485:Eczema / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007223:Infant; D009824:Ointments; D017410:Practice Guidelines as Topic; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000305:Adrenal Cortex Hormones; D065095:Calcineurin Inhibitors; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D009824:Ointments; C117268:pimecrolimus; D016559:Tacrolimus